Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors.
about
An Inducible TGF-β2-TGFβR Pathway Modulates the Sensitivity of HNSCC Cells to Tyrosine Kinase Inhibitors Targeting Dominant Receptor Tyrosine Kinases.Small molecule tyrosine kinase inhibitors of ErbB2/HER2/Neu in the treatment of aggressive breast cancer.HER3 as a Therapeutic Target in Cancer.SAR and QSAR study on the bioactivities of human epidermal growth factor receptor-2 (HER2) inhibitors.
P2860
Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors.
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Discovery of AZD8931, an Equip ...... GFR, HER2, and HER3 Receptors.
@ast
Discovery of AZD8931, an Equip ...... GFR, HER2, and HER3 Receptors.
@en
type
label
Discovery of AZD8931, an Equip ...... GFR, HER2, and HER3 Receptors.
@ast
Discovery of AZD8931, an Equip ...... GFR, HER2, and HER3 Receptors.
@en
prefLabel
Discovery of AZD8931, an Equip ...... GFR, HER2, and HER3 Receptors.
@ast
Discovery of AZD8931, an Equip ...... GFR, HER2, and HER3 Receptors.
@en
P2093
P2860
P356
P1476
Discovery of AZD8931, an Equip ...... GFR, HER2, and HER3 Receptors.
@en
P2093
Bernard Barlaam
Cath Trigwell
Christine Lambert-van der Brempt
D Mark Hickinson
Donald Ogilvie
George Kirk
Jason G Kettle
John Vincent
Judith Anderton
Laurent F A Hennequin
P2860
P304
P356
10.1021/ML400146C
P577
2013-05-31T00:00:00Z